Anti-Cancer Agent "Xeloda®", Obtained Approval for Additional Indication of "Adjuvant Chemotherapy for Rectal Cancer"

Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Condition:   Rectal Cancer Intervention:   Drug: Chemotherapy Sponsors:   King Abdullah Medical City;   King Faisal Specialist Hospital & Research Center;   King Saud Medical City;   Al Hada Military Hospital Recruiting
Source: - Category: Research Source Type: clinical trials
BACKGROUND: Adjuvant chemotherapy after curative resection for rectal cancer is the standard of care in several American and European guidelines. OBJECTIVE: The aim of this study was to examine the differences in health-related quality of life over time between patients with rectal cancer who were treated with adjuvant chemotherapy or observation. DESIGN: This is a randomized controlled phase III trial. SETTINGS: Health-related quality-of-life assessments were conducted in Dutch patients from 43 institutes. PATIENTS: Patients with stage II or III rectal cancer who underwent preoperative (chemo)radiotherapy fo...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions: Colorectal Cancer Source Type: research
It is recommended postoperative adjuvant chemotherapy for all rectal cancers undergoing neo-chemoradiotherapy regardless of the final yield pathology. However, the role of adjuvant chemotherapy in pathological...
Source: Cancer Cell International - Category: Cancer & Oncology Authors: Tags: Primary research Source Type: research
In conclusion, we identified high genomic instability in LARC, which was related to alterations in the HR pathway, especially in pIR. These findings suggest that patients with impaired HRD would clinically benefit from PARP-inhibitors and platinum-based therapy.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
ConclusionSuspicious isolated recurrences of rectal cancer in unusual locations may require surgical excision to confirm definitive diagnosis.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
CONCLUSION: Total neoadjuvant therapy should be considered in patients with high-risk locally advanced rectal cancer owing to improved chemotherapy compliance and disease control. Further prospective studies are required to determine whether this approach translates into improved disease-related survival or increases the proportion of patients suitable for non-operative management. PMID: 31074508 [PubMed - as supplied by publisher]
Source: The British Journal of Surgery - Category: Surgery Authors: Tags: Br J Surg Source Type: research
Authors: Guadagni S, Fiorentini G, Palumbo P, Masedu F, Ricevuto E, Bruera G, Deraco M, Kusamura S, Sarti D, Fiorentini C, Gailhofer S, Clementi M Abstract BACKGROUND: Patients with unresectable recurrent rectal cancer that progresses after systemic chemotherapy and radiotherapy may be candidates for palliation with hypoxic pelvic perfusion (HPP). The aim of this observational retrospective study was to evaluate if a multimodality treatment including HPP and targeted-therapy may be useful to prolong clinical responses and survival of these patients. METHODS: Thirty-seven patients with unresectable recurrent rec...
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
AbstractRectal cancer accounts for one-third of newly diagnosed colorectal cancer cases. Given its anatomical location and risk for local recurrence, a multidisciplinary treatment program including surgery, radiation therapy, and chemotherapy has demonstrated improved outcomes in localized disease. Genetic analysis has become part of the standard approach for management of advanced disease and new trials are considering tailored therapies for locally advanced disease. This review describes molecular subsets of colorectal cancer; implications for clinical management, including patterns of metastatic spread and response to t...
Source: Abdominal Imaging - Category: Radiology Source Type: research
Abstract Rectal cancer response to neoadjuvant chemoradiotherapy (pCRT) is highly variable. In fact, it has been estimated that only about 21 % of patients show pathologic complete response (pCR) after therapy, while in the most of the patients a partial or incomplete tumour regression are observed. Consequently, patients with a priori chemoradioresistant tumour should not receive the treatment, which is associated with substantial adverse effects and does not guarantee any clinical benefit. Despite for locally advanced rectal cancer patients (LARC) a standardized neoadjuvant treatment protocol is applied, the ide...
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
Abstract The combination of cetuximab (CTX) and chemotherapy, such as FOLFOX or FOLFIRI, is currently the standard treatment for metastatic colorectal cancer (mCRC). Zoledronic acid (ZOL) is used in patients with bone metastasis. We herein report our experience with the case of a 58-year-old male patient with metastatic rectal cancer who was treated with ZOL + CTX as third-line therapy, and in whom this combination appeared to be effective. Although the patient developed bone metastasis and cardiac tamponade due to the recurrence of rectal cancer, he survived for approximately 10 months after the initiation of ZOL...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Pharmaceuticals | Rectal Cancers | Xeloda